Abstract
Objective: To investigate the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and changes in cognition and global brain structure. Methods: In the Rotterdam Study, baseline NT-proBNP was assessed at baseline from 1997 to 2008. Between 1997 and 2016, participants without dementia or stroke at baseline (n = 9566) had repeated cognitive tests (every 3–6 years) for global cognitive function, executive cognitive function, fine manual dexterity, and memory. Magnetic resonance imaging of the brain was performed repeatedly at re-examination visits between 2005 and 2015 for 2607 participants to obtain brain volumes, focal brain lesions, and white matter microstructural integrity as measures of brain structure. Results: Among 9566 participants (mean age 65.1 ± 9.8 years), 5444 (56.9%) were women, and repeated measures of cognition were performed during a median follow-up time of 5.5 (range 1.1–17.9) years, of whom 2607 participants completed at least one brain imaging scan. Higher levels of NT-proBNP were associated with a faster decline of scores in the global cognitive function (p value = 0.003) and the Word-Fluency test (p value = 0.003) but were not related to a steeper deterioration in brain volumes, global fractional anisotropy, and mean diffusivity, as indicators of white matter microstructural integrity, or focal brain lesions. Conclusions: Higher baseline NT-proBNP levels were associated with a faster decline in cognition; however, no association with global brain structure was found.
| Original language | English |
|---|---|
| Pages (from-to) | 2230-2239 |
| Number of pages | 10 |
| Journal | European Journal of Neurology |
| Volume | 30 |
| Issue number | 8 |
| Early online date | 10 May 2023 |
| DOIs | |
| Publication status | Published - Aug 2023 |
Bibliographical note
Funding Information:This study was approved by the medical ethics committee of the Erasmus Medical Centre (Rotterdam, the Netherlands), and the review board of the Netherlands Ministry of Health, Welfare and Sports (1068889-159521-PG). All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. All authors had access to the study data and take full responsibility for the data, analyses, and interpretation of results. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.
Funding Information:
This research was partly performed as part of the Netherlands Consortium of Dementia Cohorts (NCDC), which receives funding in the context of Delta plan Dementia from ZonMW Memorable (projector 73305095005) and Alzheimer Nederland. Further funding was obtained through the Stitching Erasmus Trustfonds (grant number 97030.2021.101.430/057/RB). The Rotterdam Study is supported by the Erasmus MC and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health Research and Development (ZonMW); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Genomics Initiative; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The funding sources had no involvement in the collection, analysis, writing, interpretation, or decision to submit the manuscript for publication.
Publisher Copyright:
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.